Eidos Therapeutics, Inc.
DelistedCIK 1731831fmd_0Z09SYRMW5BW25JQDNKHDV59WWManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2016 to Sep 30, 2020, 16 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 |
|---|---|---|---|---|
| Total revenues | – | – | – | 27 |
| Cost of revenue | – | – | – | 3 |
| Gross profit | – | – | – | 24 |
| Research and development | 2 | 9 | 29 | 47 |
| Total operating expenses | 2 | 12 | 38 | – |
| Operating income | (2) | (12) | (38) | (40) |
| Interest expense | – | – | 1 | 0 |
| Other non-operating income (expense) | (0) | 0 | (2) | 3 |
| Net income | (3) | (12) | (41) | (38) |
| Net income to common shareholders | (3) | (12) | (40) | (38) |